Cape Girardeau, Missouri news highlights UC clinical trial
Study to test neurostimulation to treat opioid withdrawal, PTSD
KFVS-TV in Cape Girardeau, Missouri highlighted a University of Cincinnati clinical trial testing a wearable neurostimulation device to help patients with opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) stick with medication treatment while finding the right dose.
UC's Joel Sprunger, principal investigator of the trial, said the medication buprenorphine is an effective treatment to help patients with OUD manage symptoms of opioid use disorder withdrawal, but there is an adjustment period of up to three months as each patient finds the right dose to manage their symptoms.
In response to this challenge, the trial will utilize the Sparrow Ascent – a patient-administered wearable device that delivers mild electrical stimulation to the cranial branches of the vagus and trigeminal nerves on and around the ear.
Sprunger said the stimulation “pumps the brakes” on the sympathetic nervous system by enhancing parasympathetic activity, helping to transition someone from fight-or-flight to “rest and digest.”
“By providing people control over that stimulation, we can empower them with a way to turn it on when needed and feel some relief,” said Sprunger, assistant professor of psychiatry and behavioral neuroscience in UC’s College of Medicine. “Their heart rate slows down, breathing slows down and there’s a lot less of a sense of panic and urgency. So that’s the key ingredient that we think will hit both PTSD and opioid withdrawal symptoms at the same time.”
The trial is enrolling patients at the Gibson Center for Behavioral Change in Cape Girardeau.
“It does give the patient some ownership and some control over their treatment,” Ryan Essex, Gibson Center chief operating officer, told KFVS. "We get to bring cutting edge treatment options to populations who are kind of our most vulnerable and don’t get access to those."
NeuroNews also highlighted the trial. Read the NeuroNews story.
Featured photo at top of woman wearing the Sparrow Ascent device. Photo/Spark Biomedical.
Related Stories
‘Designer drug’ shows early neuroprotective signal in acute ischemic stroke
October 28, 2025
Medscape highlighted new trial results led by the University of Cincinnati's Eva Mistry that found an experimental drug shows promise in protecting injured brain cells for patients with acute ischemic stroke.
UC Board votes to fund design for YMCA renovation
October 28, 2025
At its October 28, 2025 meeting, the University of Cincinnati Board of Trustees approved $5 million in funding to complete all design and pre-construction services required to renovate the interior of a former YMCA building located at 270 Calhoun Street.
Is menstrual fluid ‘the most overlooked opportunity’ in women’s health?
October 27, 2025
The Guardian recently reported that period blood has long been thought of as ‘stinky and useless’, but startups are exploring using the fluid to test for a wide range of health conditions — including endometriosis.